Sofia Vlasova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sofia Vlasova has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Heather J. Bax
King’s College London
2 shared publications - Jitesh Chauhan
St. John's Institute of Dermatology, School of Basic and Medical Biosciences & KHP Centre for Translational Medicine King's College London, Guy's Hospital London UK
2 shared publications - Sophia N. Karagiannis
King’s College London
2 shared publications Alex J McCraw
St. John’s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK
1 shared publicationAlicia Chenoweth
St. John’s Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK
1 shared publication- Alicia M. Chenoweth
King’s College London
1 shared publication
Latest Publications
- Open Access
Basophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation Test
Basophils, the least abundant leukocytes, are increasingly recognised as potent immunomodulators. Upon activation, they rapidly release preformed granule‐associated mediators including histamine and lipid mediators such as LTC 4 , while cytokine production occurs over a longer timescale, contributing to downstream immune responses. Basophil activation is driven by IgE‐dependent FcεRI crosslinking or IL‐3, complement and Toll‐like receptor (TLR) pathways, enabling diverse effector responses, including type I hypersensitivity to allergens. Through IL‐4 and IL‐13 secretion, basophils bridge innate and adaptive immunity, promoting Th2 differentiation, B cell activation and recruiting eosinophils. Beyond allergy, basophils contribute to inflammation, angiogenesis, cancer immune surveillance and tumour progression. Basophils participate in IgE‐dependent type I hypersensitivity to small‐molecule drugs, chemotherapeutics and monoclonal antibodies, becoming activated when drugs cross‐link specific IgE–FcεRI complexes, driving rapid mediator release and amplifying Th2‐skewed inflammation. The basophil activation test (BAT), which quantifies activation markers, such as CD63 and CD203c, provides an ex vivo functional measurement of these responses and serves as a biomarker of IgE‐mediated hypersensitivity. In oncology, BAT is applied to predict and monitor hypersensitivity reactions, drug desensitisation and support IgE‐based therapeutics development. Collectively, basophils are emerging as pivotal immune regulators and BAT presents a mechanistic, clinically‐actionable tool for advancing precision medicine in AllergoOncology.
Open AccessBasophils in Immunity: Activation Pathways, Roles in Allergy and AllergoOncology and Application of the Basophil Activation Test
Basophils, the least abundant leukocytes, are increasingly recognised as potent immunomodulators. Upon activation, they rapidly release preformed granule‐associated mediators including histamine and lipid mediators such as LTC 4 , while cytokine production occurs over a longer timescale, contributing to downstream immune responses. Basophil activation is driven by IgE‐dependent FcεRI crosslinking or IL‐3, complement and Toll‐like receptor (TLR) pathways, enabling diverse effector responses, including type I hypersensitivity to allergens. Through IL‐4 and IL‐13 secretion, basophils bridge innate and adaptive immunity, promoting Th2 differentiation, B cell activation and recruiting eosinophils. Beyond allergy, basophils contribute to inflammation, angiogenesis, cancer immune surveillance and tumour progression. Basophils participate in IgE‐dependent type I hypersensitivity to small‐molecule drugs, chemotherapeutics and monoclonal antibodies, becoming activated when drugs cross‐link specific IgE–FcεRI complexes, driving rapid mediator release and amplifying Th2‐skewed inflammation. The basophil activation test (BAT), which quantifies activation markers, such as CD63 and CD203c, provides an ex vivo functional measurement of these responses and serves as a biomarker of IgE‐mediated hypersensitivity. In oncology, BAT is applied to predict and monitor hypersensitivity reactions, drug desensitisation and support IgE‐based therapeutics development. Collectively, basophils are emerging as pivotal immune regulators and BAT presents a mechanistic, clinically‐actionable tool for advancing precision medicine in AllergoOncology.
- Open Access
- 12 March 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (3) , e010945
Fc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors
Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant tumors retain antigen expression and therefore remain potentially targetable with anti-HER2 therapies that promote immune-mediated responses. Tumor-antigen-specific IgE class antibodies can mediate powerful immune cell-mediated effects against different cancers and have been shown to activate IgE Fc receptor-expressing monocytes. We previously reported the engineering of a trastuzumab-equivalent anti-HER2 IgE antibody and showed early evidence of Fc-mediated cancer cell-targeting effects. In the present study, we evaluated the anti-tumoral functions of two anti-HER2 IgEs, trastuzumab and pertuzumab IgE. Methods: In vitro functionality of the two anti-HER2 antibodies was assessed by HER2 phosphorylation and ligand-independent viability assays, as well as basophil (RBL-SX38) degranulation, antibody-dependent cellular cytotoxicity/antibody-dependent cellular phagocytosis(ADCC/ADCP) assays and primary monocyte stimulation assays. The potential to trigger a hypersensitivity type I reaction was investigated using the basophil activation test (BAT). anti-tumoral efficacy was assessed in two humanized HER2+, trastuzumab-resistant models in vivo. Changes in the tumor microenvironment were assessed by flow cytometry or bulk RNA sequencing. Results: We demonstrate the anti-tumoral and immunostimulatory functions of two anti-HER2 IgEs derived from variable region sequences of the clinically available trastuzumab and pertuzumab IgG1 antibodies. IgE engagement of monocytes via the Fc region induced tumor cell cytotoxicity and a pro-inflammatory shift with upregulation of immune-stimulatory CD40, CD80 and CD86, and downregulation of scavenger CD163, cell surface molecules. This was accompanied by enhanced pro-inflammatory tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β cytokine production. The absence of basophil activation by anti-HER2 IgEs ex vivo in whole blood points to potentially safe administration in humans. In two trastuzumab-resistant HER2+ tumor xenograft models in immunodeficient mice reconstituted with human immune cells, the trastuzumab-equivalent anti-HER2 IgE restricted tumor growth. Treatment was associated with enriched classical (CD14+CD16–) monocyte and lower alternatively-activated (CD163+CD206+) macrophage infiltration, and higher densities of activated CD4+ (CD127loCD25hi) T cells and favorable effector T cell(Teff) to regulatory T cell (Treg) ratios in tumors. Conclusion: Collectively, anti-HER2 IgE maintains Fab-mediated antitumor activity, induces Fc-mediated effects against HER2-expressing tumor cells, and stimulates remodeling of the immune microenvironment in tumors to promote pro-inflammatory cell phenotypes which could translate to improved outcomes for patients.
- 12 March 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (3) , e010945
Open AccessFc-mediated immune stimulating, pro-inflammatory and antitumor effects of anti-HER2 IgE against HER2-expressing and trastuzumab-resistant tumors
Background: Anti-human epidermal growth factor receptor 2 (HER2) IgG1-based antibody therapies significantly improve cancer prognosis, yet intrinsic or acquired resistance to fragment antigen-binding (Fab)-mediated direct effects commonly occurs. Most resistant tumors retain antigen expression and therefore remain potentially targetable with anti-HER2 therapies that promote immune-mediated responses. Tumor-antigen-specific IgE class antibodies can mediate powerful immune cell-mediated effects against different cancers and have been shown to activate IgE Fc receptor-expressing monocytes. We previously reported the engineering of a trastuzumab-equivalent anti-HER2 IgE antibody and showed early evidence of Fc-mediated cancer cell-targeting effects. In the present study, we evaluated the anti-tumoral functions of two anti-HER2 IgEs, trastuzumab and pertuzumab IgE. Methods: In vitro functionality of the two anti-HER2 antibodies was assessed by HER2 phosphorylation and ligand-independent viability assays, as well as basophil (RBL-SX38) degranulation, antibody-dependent cellular cytotoxicity/antibody-dependent cellular phagocytosis(ADCC/ADCP) assays and primary monocyte stimulation assays. The potential to trigger a hypersensitivity type I reaction was investigated using the basophil activation test (BAT). anti-tumoral efficacy was assessed in two humanized HER2+, trastuzumab-resistant models in vivo. Changes in the tumor microenvironment were assessed by flow cytometry or bulk RNA sequencing. Results: We demonstrate the anti-tumoral and immunostimulatory functions of two anti-HER2 IgEs derived from variable region sequences of the clinically available trastuzumab and pertuzumab IgG1 antibodies. IgE engagement of monocytes via the Fc region induced tumor cell cytotoxicity and a pro-inflammatory shift with upregulation of immune-stimulatory CD40, CD80 and CD86, and downregulation of scavenger CD163, cell surface molecules. This was accompanied by enhanced pro-inflammatory tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1β cytokine production. The absence of basophil activation by anti-HER2 IgEs ex vivo in whole blood points to potentially safe administration in humans. In two trastuzumab-resistant HER2+ tumor xenograft models in immunodeficient mice reconstituted with human immune cells, the trastuzumab-equivalent anti-HER2 IgE restricted tumor growth. Treatment was associated with enriched classical (CD14+CD16–) monocyte and lower alternatively-activated (CD163+CD206+) macrophage infiltration, and higher densities of activated CD4+ (CD127loCD25hi) T cells and favorable effector T cell(Teff) to regulatory T cell (Treg) ratios in tumors. Conclusion: Collectively, anti-HER2 IgE maintains Fab-mediated antitumor activity, induces Fc-mediated effects against HER2-expressing tumor cells, and stimulates remodeling of the immune microenvironment in tumors to promote pro-inflammatory cell phenotypes which could translate to improved outcomes for patients.